European Journal of Cancer最新文献

{"title":"Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients","authors":"C. Robert ,&nbsp;G.V. Long ,&nbsp;J. Larkin ,&nbsp;J.D. Wolchok ,&nbsp;J.C. Hassel ,&nbsp;D. Schadendorf ,&nbsp;F.S. Hodi ,&nbsp;C. Lebbé ,&nbsp;J.-J. Grob ,&nbsp;J.R. Hyngstrom ,&nbsp;J. Wagstaff ,&nbsp;J. Chesney ,&nbsp;M.O. Butler ,&nbsp;O. Bechter ,&nbsp;I. Márquez-Rodas ,&nbsp;A.C. Pavlick ,&nbsp;P. Durani ,&nbsp;M. Pe Benito ,&nbsp;P. Wang ,&nbsp;M.A. Postow ,&nbsp;P.A. Ascierto","doi":"10.1016/j.ejca.2024.115119","DOIUrl":"10.1016/j.ejca.2024.115119","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the predictive value of RECIST response within 3, 6, or 12 months on long-term survival, and explore differences between nivolumab+ipilimumab and nivolumab monotherapy, we analyzed pooled 5-year data of 935 responder and non-responder patients at various time points after treatment initiation in CheckMate 069, 066, and 067 studies.</div></div><div><h3>Patients and methods</h3><div>Treatment-naive advanced melanoma patients received nivolumab+ipilimumab or nivolumab monotherapy. To decrease immortal time bias, 3-, 6-, or 12-month overall survival (OS) and progression-free survival (PFS) landmark analyses were performed. Association between characteristics and response was evaluated by univariate and multivariate analyses.</div></div><div><h3>Results</h3><div>Response rates at any time were 58 % (239/409) for nivolumab+ipilimumab and 44 % (230/526) for nivolumab monotherapy. In 12-month landmark analyses, 5-year OS rates for responders versus non-responders were 82 % versus 40 % with nivolumab+ipilimumab (HR=0.23 [95 % CI, 0.15–0.35]) and 76 % versus 32 % with nivolumab monotherapy (HR=0.22 [95 % CI, 0.16–0.31]). PFS rates were 83 % versus 32 % and 69 % versus 46 %, respectively. Similar strong associations between response at 3 and 6 months and 5-year OS and PFS were also observed with more than 70 % of the responses observed in the first 3 months. Response rates correlated with baseline LDH and PD-L1 status by multivariate analysis but the association between response and long-term survival was maintained in landmark analyses even among patients with high LDH and low PD-L1 expression.</div></div><div><h3>Conclusion</h3><div>Clinical response evaluated in the first months of therapy is a strong predictor of long-term survival, even in patients with poor prognostic biomarkers.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"Article 115119"},"PeriodicalIF":7.6,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142722102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma","authors":"James P. Pham ,&nbsp;Ramon Staeger ,&nbsp;Anthony M. Joshua ,&nbsp;Jia Liu ,&nbsp;Ines P. da Silva ,&nbsp;Reinhard Dummer ,&nbsp;Simone M. Goldinger","doi":"10.1016/j.ejca.2024.115121","DOIUrl":"10.1016/j.ejca.2024.115121","url":null,"abstract":"<div><div>Over the last decade, immune checkpoint inhibitors (ICIs) have been established as an integral component of the contemporary anticancer armamentarium. In dermatology, ICIs are most established as treatment of advanced melanoma. However, emerging evidence has demonstrated that their utility in cutaneous oncology extends to a variety of other non-melanoma malignancies. This review provides an update of the evidence from clinical trials, real world analyses, and translational research over the last three years in cutaneous malignancies beyond melanoma. Special focus is presented on areas warranting further evaluation – including populations underrepresented in or excluded from clinical trials; new and emerging treatment scenarios beyond patients with metastatic disease; novel combination approaches; and the urgent need for reliable predictive biomarkers to identify predictors of response. Collaboration between oncologists, dermatologists and dermatological surgeons is essential to progress our understanding and treatment of patients with advanced cutaneous malignancies.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"Article 115121"},"PeriodicalIF":7.6,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142700569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study” [Eur J Cancer 196 (2024) 113424]","authors":"Pien Debets ,&nbsp;Koen M.A. Dreijerink ,&nbsp;Anton F. Engelsman ,&nbsp;Max Dahele ,&nbsp;Harm R. Haak ,&nbsp;Rebecca V. Steenaard ,&nbsp;Ellen Kapiteijn ,&nbsp;Eleonora Corssmit ,&nbsp;C. Willemien Menke-van der Houven van Oordt","doi":"10.1016/j.ejca.2024.115123","DOIUrl":"10.1016/j.ejca.2024.115123","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115123"},"PeriodicalIF":7.6,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials","authors":"Akshay J. Patel ,&nbsp;Hanan Hemead ,&nbsp;Jacie Law ,&nbsp;Anuj Wali ,&nbsp;Paulo De Sousa ,&nbsp;Eric Lim","doi":"10.1016/j.ejca.2024.115118","DOIUrl":"10.1016/j.ejca.2024.115118","url":null,"abstract":"<div><h3>Background</h3><div>We sought to investigate the relative impact of the timing of the administration of immunotherapy on survival in patients with resectable lung cancer.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of randomised controlled trials in this setting. We searched MEDLINE, EMBASE, LILACS and Cochrane Library databases from 1st January 1980 onwards. We excluded case reports; non-randomised studies; studies without an immunotherapy arm and if there was incomplete reporting on outcome data including conference abstracts. A standardised, pre-piloted form was used to extract data from the included studies for the assessment of study quality and for evidence synthesis. The primary outcome measure was overall survival which was assessed using random-effects meta-analyses (DerSimonian and Laird). The study was registered with PROSPERO (CRD42023407825).</div></div><div><h3>Findings</h3><div>We screened 865 studies and assessed 58 full text articles after removing non-human, non-surgical studies. These studies collectively enrolled 4982 participants and 4425 were included in the respective analyses. Hazard ratios (HRs) for death by timing of administration of immunotherapy, i.e., Neoadjuvant (pre-operative), peri-operative and post-operative were 0.57 (95 % CI 0.302–1.08), 0.67 (95 % CI 0.39–1.13) and 0.94 (95 % CI 0.29–3.06) respectively. The timing of administration accounted for 100 % of the difference in true effect size (test of moderators (Q_M p = 0.127), residual I² 0 %, p = 0.561). OR for adverse events was higher in the neoadjuvant setting compared to the peri-operative setting; 1.49 (0.64–3.47) and 1.34 (1.08–1.66) respectively. Bias assessment found the majority of studies to be low risk with respect to random sequencing, incomplete outcomes, and selective reporting.</div></div><div><h3>Interpretation</h3><div>In resectable non-small cell lung cancer, administration of adjuvant chemo-immunotherapy regimens in clinical trials did not lead to statistically significant survival benefits. Overall survival outcomes of neoadjuvant and peri-operative chemo-immunotherapy were comparable, but given the shorter duration and lower costs, neoadjuvant chemo-immunotherapy can be considered the current multimodality combination of choice.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"214 ","pages":"Article 115118"},"PeriodicalIF":7.6,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomic features of primary retroperitoneal sarcomas: a prognostic study","authors":"Sandro Pasquali ,&nbsp;Sara Iadecola ,&nbsp;Andrea Vanzulli ,&nbsp;Gabriele Infante ,&nbsp;Marco Bologna ,&nbsp;Valentina Corino ,&nbsp;Gabriella Greco ,&nbsp;Raffaella Vigorito ,&nbsp;Carlo Morosi ,&nbsp;Alessia Beretta ,&nbsp;Stefano Percio ,&nbsp;Viviana Vallacchi ,&nbsp;Paola Collini ,&nbsp;Roberta Sanfilippo ,&nbsp;Chiara Fabbroni ,&nbsp;Silvia Stacchiotti ,&nbsp;Marco Fiore ,&nbsp;Paul Huang ,&nbsp;Matteo Benelli ,&nbsp;Luca Mainardi ,&nbsp;Dario Callegaro","doi":"10.1016/j.ejca.2024.115120","DOIUrl":"10.1016/j.ejca.2024.115120","url":null,"abstract":"<div><h3>Background</h3><div>Risk-stratification of patients with retroperitoneal sarcomas (RPS) relies on validated nomograms, such as Sarculator. This retrospective study investigated whether radiomic features extracted from computed tomography (CT) imaging could <em>i</em>) enhance the performance of Sarculator and <em>ii</em>) identify G3 dedifferentiated liposarcoma (DDLPS) or leiomyosarcoma (LMS), which are currently consider in a randomized clinical trial testing neoadjuvant chemotherapy.</div></div><div><h3>Methods</h3><div>Patients with primary localized RPS treated with curative-intent surgery (2011–2015) and available pre-operative CT imaging were included. Regions of interest (ROIs) were manually annotated on both unenhanced and portal venous phase acquisitions. Top performing radiomic features were selected with outcome-specific random forest models, through generation of replicative experiments (contexts) where patients were split into training and testing sets. Endpoints were overall and disease-free survival (OS, DFS).</div><div>Prognostic models for DFS and OS included the top five selected radiomic features and the Sarculator nomogram score.</div><div>Models accuracy was assessed with Harrell’s Concordance (C-)index.</div></div><div><h3>Results</h3><div>The study included 112 patients, with a median follow-up of 77 months (IQR 65–92 months).</div><div>Sarculator alone achieved a C-index of 0.622 and 0.686 for DFS and OS, respectively. Radiomic features only marginally enhanced the prediction accuracy of Sarculator for OS (C-index=0.726, C-index gain: 0.04) or DFS (C-index=0.639, C-index gain: 0.017). Finally, radiomic features identified patients with G3 DDLPS or LMS with an accuracy of 0.806.</div></div><div><h3>Conclusion</h3><div>Radiomic features marginally improved the performance of Sarculator in RPS.</div><div>However, they accurately identified G3 DDLPS or LMS at diagnosis, potentially improving patients selection for neoadjuvant treatments.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115120"},"PeriodicalIF":7.6,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCCA variant rs16957301 is a novel AKI risk genotype-specific for patients who receive ICI treatment: Real-world evidence from all of us cohort","authors":"Yanfei Wang ,&nbsp;Chenxi Xiong ,&nbsp;Weifeng Yu ,&nbsp;Minghao Zhou ,&nbsp;Tyler Shugg ,&nbsp;Fang-Chi Hsu ,&nbsp;Michael T. Eadon ,&nbsp;Jing Su ,&nbsp;Qianqian Song","doi":"10.1016/j.ejca.2024.115114","DOIUrl":"10.1016/j.ejca.2024.115114","url":null,"abstract":"<div><h3>Introduction</h3><div>Immune checkpoint inhibitors (ICIs) enhance the immune system's ability to target and destroy cancer cells, but can also trigger immune-related adverse events (irAEs), such as acute kidney injury (ICI-AKI), complicating patient management. Limited knowledge of genetic predispositions to ICI-AKI highlights the need for genomic studies to improve therapeutic strategies.</div></div><div><h3>Objective</h3><div>To identify genetic predispositions for ICI-AKI using large-scale real-world data.</div></div><div><h3>Methods</h3><div>A systematic literature search led to 14 candidate variants related to irAEs. We performed a candidate variant association study with these variants using the All of Us cohort. An ICI-treated cohort and a general cohort were established to evaluate ICI-AKI risk. Logistic regression, adjusted for sex, evaluated the impact of each candidate genotype, separately for self-reported and ancestry-estimated race. Kaplan-Meier survival analysis assessed genetic effects on AKI-free survival.</div></div><div><h3>Results</h3><div>The ICI cohort (n = 414) showed a one-year AKI incidence rate of 23.2 %, significantly higher than the general cohort (6.5 %, n = 213,282). The rs16957301 variant (chr13:100324308, T &gt; C) in the <em>PCCA</em> gene was a significant risk genotype for ICI-AKI among self-reported White (Beta=0.93, CI: 0.32 – 1.54, ORs= 2.53, Bonferroni-corrected P-value=0.047) and ancestry estimated Europeans (Beta = 0.94, CI: 0.31 – 1.57, ORs= 2.56, Bonferroni-corrected P-value=0.044). Self-reported White with the rs16957301 risk genotypes (TC/CC) developed AKI significantly earlier (3.6 months) compared to the reference genotype (TT, 7.0 months, log-rank P = 0.04). Consistent results were found in ancestry-estimated Europeans. This variant did not present significant AKI risks in the general cohort (Beta: −0.008–0.035, FDR: 0.75–0.99).</div></div><div><h3>Conclusion</h3><div>Our findings suggest that rs16957301 in PCCA may serve as an ICI-AKI risk marker in Caucasians. Further studies are needed to validate this association and explore risks in other populations.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115114"},"PeriodicalIF":7.6,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials","authors":"Steven Sorscher ,&nbsp;Caio Max Sao Padro Rocha Lima","doi":"10.1016/j.ejca.2024.115112","DOIUrl":"10.1016/j.ejca.2024.115112","url":null,"abstract":"","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115112"},"PeriodicalIF":7.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01","authors":"Hisashi Tanaka ,&nbsp;Tomonori Makiguchi ,&nbsp;Takehiro Tozuka ,&nbsp;Yosuke Kawashima ,&nbsp;Tomohiro Oba ,&nbsp;Ryosuke Tsugitomi ,&nbsp;Junji Koyama ,&nbsp;Yuichi Tambo ,&nbsp;Shinsuke Ogusu ,&nbsp;Masafumi Saiki ,&nbsp;Hiroshi Gyotoku ,&nbsp;Tsukasa Hasegawa ,&nbsp;Eisaku Miyauchi ,&nbsp;Tomoaki Sonoda ,&nbsp;Ryota Saito ,&nbsp;Katsumi Nakatomi ,&nbsp;Toshio Sakatani ,&nbsp;Keita Kudo ,&nbsp;Yuko Tsuchiya-Kawano ,&nbsp;Makoto Nishio","doi":"10.1016/j.ejca.2024.115117","DOIUrl":"10.1016/j.ejca.2024.115117","url":null,"abstract":"<div><h3>Introduction</h3><div>Immune checkpoint inhibitors (ICIs) plus chemotherapy is now a standard treatment for non-small cell lung cancer (NSCLC). Whether ICI plus chemotherapy (ICI-chemo) or ipilimumab plus nivolumab (I-N)-based therapy is superior for patients with NSCLC with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1–49 % has not been evaluated.</div></div><div><h3>Methods</h3><div>This multicenter retrospective study included NSCLC patients with a TPS score of 1–49 %, who began first-line chemotherapy. Propensity score matching analysis was used to adjust for various confounders and evaluate treatment efficacy.</div></div><div><h3>Results</h3><div>A total of 401 patients were enrolled, of whom 308 received ICI-chemo and 93 received I-N-based therapy. The median OS was 21.0 months in the ICI-chemo group and 20.0 months in the I-N-based therapy group. After propensity score matching, there was no difference in OS or PFS between the ICI-chemo group and the I-N-based therapy group (OS: hazard ratios (HR), 0.83; 95 % confidence interval [CI], 0.54–1.26, PFS: HR, 0.72; 95 % CI, 0.52–1.00). Among PD-L1 TPS 25–49 %, there was a tendency for OS to be favorable for the ICI-chemo group (OS: HR, 0.30; 95 % CI, 0.09–0.85). Treatment discontinuation occurred for 26.2 % of the patients in the ICI-chemo group and 41.9 % in the I-N-based therapy group.</div></div><div><h3>Conclusions</h3><div>Among PD-L1 TPS 1–49 %, there was no significant difference in survival outcomes between the ICI-chemo group and the I-N-based therapy group. Based on the results of a subgroup analysis, ICI-chemo may be superior for treating NSCLC with a TPS of 25–49 %.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115117"},"PeriodicalIF":7.6,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of invasive lung cancer in pure ground glass nodules less than 30 mm: A systematic review","authors":"Abdullah AlShammari ,&nbsp;Akshay Patel ,&nbsp;Mark Boyle ,&nbsp;Chiara Proli ,&nbsp;Jose Alvarez Gallesio ,&nbsp;Anuj Wali ,&nbsp;Paulo De Sousa ,&nbsp;Eric Lim","doi":"10.1016/j.ejca.2024.115116","DOIUrl":"10.1016/j.ejca.2024.115116","url":null,"abstract":"<div><h3>Background</h3><div>The IASLC TNM proposal suggests that pure ground glass nodules less than 30 mm should be classified as cTis corresponding to pathologic adenocarcinoma in situ implying no invasive malignancy potential. We sought to ascertain the proportion of pure ground glass nodules that harbour tissue confirmed minimally invasive or invasive adenocarcinoma.</div></div><div><h3>Methods</h3><div>We analyzed data from 3874 individuals with pure ground glass nodules less than 30 mm, reported in 28 observational studies identified through a systematic search of electronic databases. The primary outcome was the prevalence of invasive malignancy by random effects meta-analysis, and we used meta-regression to determine the impact of baseline risk, size, and country of investigation on overall effect size. The study was registered with PROSPERO (CRD42021286261).</div></div><div><h3>Results</h3><div>All published studies were retrospective (n = 28) and the majority conducted in Asia (n = 25). Baseline patient cohorts were mainly from published surgical series (n = 22) or lung cancer screening programs (n = 6). The proportion of minimally invasive and invasive cancer ranged from 0.9 % to 100 % with a pooled prevalence of 42.4 % [95 % CI: 0.28, 0.57].</div><div>Considerable heterogeneity was observed (I₂ =99 %) and patient selection was the most significant contribution, accounting for 73 % of the observed heterogeneity (p &lt; 0.0001). Meta-regression based on size selection and country of investigation revealed no significant contribution to effect size effect or heterogeneity.</div></div><div><h3>Conclusions</h3><div>Pure ground glass nodules less than 30 mm harbour a high proportion of invasive malignancy, contrary to the IASLC staging proposals and opinions from numerous guidelines across the world.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115116"},"PeriodicalIF":7.6,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FIGO 2023 staging for endometrial cancer, when, if it is not now?","authors":"Xavier Matias-Guiu ,&nbsp;Sigurd Lax ,&nbsp;Maria Rosaria Raspollini ,&nbsp;Jose Palacios ,&nbsp;Wenxin Zheng ,&nbsp;Congrong Liu ,&nbsp;Louise de Brot ,&nbsp;Leonardo Lordello ,&nbsp;David Hardisson ,&nbsp;David Gaffney ,&nbsp;David Mutch ,&nbsp;Giovanni Scambia ,&nbsp;Carien L. Creutzberg ,&nbsp;Christina Fotopoulou ,&nbsp;Jonathan S. Berek ,&nbsp;Nicole Concin","doi":"10.1016/j.ejca.2024.115115","DOIUrl":"10.1016/j.ejca.2024.115115","url":null,"abstract":"<div><div>Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":"Article 115115"},"PeriodicalIF":7.6,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}